Day: December 1, 2020

バミューダ諸島ハミルトン発, Dec. 02, 2020 (GLOBE NEWSWIRE) — エンスター･グループ･リミテッド (Enstar Group Limited、NASDAQ: ESGR) (以下「エンスター」) は本日、スターストーンU.S. (StarStone U.S. Holdings, Inc.) (以下「スターストーンU.S.」) の売却と資本増強を完了したことを発表した。この取引では、現金とコアスペシャルティ保険 (Core Specialty Insurance Holdings, Inc.) (以下「コアスペシャルティ」) の株式約25%を組み合わせて交換することで、スターストーンU.S.をコアスペシャルティに売却した。規制当局の承認を受け、その他各種の完了条件が満たされたことで、取引は完了した。スカイナイト･キャピタル (SkyKnight Capital, L.P.)、ドラゴニア･インベストメント･グループ (Dragoneer Investment Group)、アクイライン･キャピタル･パートナーズ (Aquiline Capital Partners LLC) とその他 (主に経営陣と取締役) のコアスペシャルティ投資家は、新たな株式資本に対して6億1,000万ドル (約634億4,000万円) を出資した。エンスターの既存の所有権のロールオーバーと経営陣およびその他の投資家からの6,000万ドル (約62億4,000万円) の出資を合わせると、同社の自己資本は9億ドル (約936億円) 以上になる。エンスターがスターストーンU.S.をコアスペシャルティに売却したのに伴い、エンスターの全額出資子会社の1社が、スターストーンU.S.のレガシー準備金に関連して、合成損失ポートフォリオとアドバース･デベロップメント再保険契約を締結した。2020年8月に締結した資本増強契約に従って、エンスターはコアスペシャルティが保有するトライデントV...

LORDSTOWN, Ohio, Dec. 01, 2020 (GLOBE NEWSWIRE) — Lordstown Motors Corp. (Nasdaq: RIDE), (“Lordstown Motors”), a leader in electric light duty trucks focused on the commercial fleet market, today announced that Steve Burns, Chief Executive Officer of Lordstown Motors, will take part in a fireside chat at the Credit Suisse Eighth Annual Virtual Industrials Conference.The discussion will be webcasted live and will take place on Wednesday, December 2, 2020 from 2:30 p.m. EST to 3:00 p.m. EST. In order to sign up for and access the event, please click here.About Lordstown Motors Corp.Lordstown Motors Corp. is an Ohio-based original equipment manufacturer of light duty fleet vehicles, founded by CEO Steve Burns with the purpose of transforming Ohio’s Mahoning Valley and Lordstown, Ohio, into the epicenter of electric-vehicle manufacturing....

GUANGZHOU, China, Dec. 01, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a public secondary offering by certain selling shareholders (the “Offering”) of 1,838,000 American Depositary Shares (“ADSs”), each representing one Class A ordinary share of the Company. The selling shareholders have granted the underwriters an option, exercisable within 30 days from the date of the final prospectus, to purchase up to 275,700 additional ADSs.The Company will not receive any proceeds from the sale of the ADSs by the selling shareholders.Morgan...

TORONTO, Dec. 01, 2020 (GLOBE NEWSWIRE) — Petrolympic Ltd. (the “Company“) (TSX-V:PCQ – OTCQB:PCQRF) is pleased to announce the closing of a non-brokered private placement (the “Offering“), consisting of 1,666,667 units (“Units“) at a price of $0.06 per Unit to raise aggregate gross proceeds of $100,000.Each Unit consists of one common share (“Common Share“) of the Company and one Common Share purchase warrant (“Warrant“). Each Warrant entitles the holder thereof to purchase a Common Share at $0.10 per share for a period of 36 months from closing, subject to acceleration in the event that the Common Shares trade at or above $0.20 for 30 consecutive trading days.Petrolympic’s Chief Executive Officer, Mendel Ekstein, commented: “In determining who would participate...

SHANGHAI, China, Dec. 02, 2020 (GLOBE NEWSWIRE) — Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the China Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA) has recommended Breakthrough Therapy Designation (BTD) for Nefecon for the treatment of IgA nephropathy (IgAN).Nefecon is a potential first-in-disease, oral, targeted-release formulation of budesonide and is currently being investigated in a Phase 3 global registrational study, NefIgArd, to evaluate its efficacy and safety in patients with primary IgAN. Everest is currently enrolling patients as part of the NefIgArd clinical trial to...

中国上海, Dec. 02, 2020 (GLOBE NEWSWIRE) — 云顶新耀 (HKEX 1952.HK)， 是一家专注于创新药研发及商业化的生物制药公司，致力于满足大中华区及亚洲其它市场未被满足的医疗需求，今日公布国家药品监督管理局药品审评中心在其官网上公示Nefecon为拟突破性治疗品种，Nefecon是云顶新耀引进开发用于治疗IgA肾病的创新药物。Nefecon 是布地奈德的口服靶向释放制剂，有潜力成为首个治疗 IgA 肾病的新药，目前正在开展一项全球3期临床研究NefIgArd，评估其对原发性IgA肾病患者的疗效和安全性。 云顶新耀目前正在招募中国IgA肾病患者加入NefIgArd临床研究，以支持Nefecon在中国的注册审批。云顶新耀的合作伙伴Calliditas Therapeutics AB （“Calliditas”，纳斯达克股票代码：CALT)于2020年11月8日公布了全球NefIgArd临床试验A部分获得良好结果，结果显示该试验Nefecon达到了其主要终点，在治疗9 个月后，患者的尿蛋白肌酐比率（或蛋白尿）在统计学上显著降低，在治疗 12 个月后，指标有了显著的持续性改善。此外，Nefecon已被美国食品药品管理局（FDA）和欧洲药品管理局（EMA）认定为治疗IgA肾病的孤儿药物。云顶新耀内科领域首席医学官朱正缨博士表示:“药品审评中心公示Nefecon为拟突破性治疗品种药物，我们深受鼓舞，这将使其有潜力成为中国约200万人IgA肾病患者的首个治疗药物。我们将积极支持配合药品审评中心的工作，尽快将这种创新疗法应用于中国患者。”云顶新耀首席执行官薄科瑞博士表示：“ Nefecon全球临床与注册工作进展迅速，在短短几个月内就取得了显著进展，包括NefIgArd 3期全球临床研究良好结果的公布，实现中国首例患者临床用药，持续开展NefIgArd临床招募，包括此次公示为拟突破性治疗品种药物。我们对此临床进展倍感振奋，我们将致力于加快Nefecon的后期研究，以便将这种创新疗法尽快带给中国的IgA肾病患者。”最新修订的《药品注册管理办法》将突破性治疗药物纳入优先审评审批的适用范围及条件，这有助于加快中国针对严重疾病开发新药，尤其是针对那些尚无现有疗法，或者有初步证据显示比现有疗法更具优势的新药解决方案。有关...

BLACK HAWK, Colo., Dec. 01, 2020 (GLOBE NEWSWIRE) — Monarch Casino & Resort, Inc. (NASDAQ: MCRI) (“Monarch” or “the Company”) today expressed their gratitude to the voters of Black Hawk and the Black Hawk City Council for their support of the November 2020 passage of Amendment 77. At a special meeting earlier today, the Black Hawk City Council approved an ordinance allowing for unrestricted bet limits as well as a resolution authorizing a variety of new casino games including baccarat, keno and pai-gow tiles, along with many popular table game side bets. The changes to bet limits and casino game offerings are expected to go into effect on May 1, 2021.John Farahi, Co-Chairman and Chief Executive Officer of Monarch, commented: “We recently began the phased opening of our all-new Monarch Casino Resort Spa Black Hawk, which represents...

DAVENPORT, Iowa, Dec. 01, 2020 (GLOBE NEWSWIRE) — Lee Enterprises, Incorporated (NYSE: LEE), a leading provider of high quality, trusted, local news and information, and a major platform for advertising in 77 markets, has scheduled an audio webcast and conference call for Thursday, December 10, 2020, at 9 a.m. Central Time. Lee plans to issue a news release before market open that day with preliminary results for its fourth fiscal quarter ended September 27, 2020.The live webcast will be accessible at lee.net and will be available for replay 24 hours later. Several analysts have been invited to ask questions on the call. Questions from other participants may be submitted by participating in the webcast. The call also may be monitored on a listen-only conference line by dialing (toll free) 800-309-1256 and entering a conference pass...